Radiopharmaceutical developer Cytogen of Princeton, NJ, has reacquired U.S. marketing rights to its Quadramet product for the relief of bone pain. Quadramet previously was sold in the U.S. under a license Cytogen had granted to Berlex Laboratories, the U.S. division of German pharmaceutical company Schering.
Cytogen said that it will begin marketing Quadramet through its in-house specialty sales force, which is already calling on urologists and radiation oncologists. Under the company’s 1998 deal with Berlex, Quadramet produced sales of $7.36 million in North and Latin America last year, of which Cytogen received $1.84 million in royalty revenue.
Cytogen will now receive all Quadramet revenue in North and Latin America, with the exception of continued royalty payments to Berlex. Schering will continue to market Quadramet in Europe under a direct license from Dow Chemical. Cytogen acquired rights to Quadramet from Dow in 1993.
By AuntMinnie.com staff writersAugust 1, 2003
Related Reading
Cytogen nets $10 million, July 11, 2003
GE, Cytogen ink fusion imaging alliance, June 24, 2003
Cytogen to reacquire Quadramet rights, June 16, 2003
Cytogen, DraxImage terminate brachytherapy agreement, April 9, 2003
Cytogen 2002 loss grows despite revenue gains, February 26, 2003
Copyright © 2003 AuntMinnie.com
